JCRB1657 HuCCA-1
Cell information
Cell type:general cells (View Pricing Information)
| JCRB No. | JCRB1657 | Cell Name | HuCCA-1 |
|---|---|---|---|
| Profile | Human cell line derived from cholangiocarcinoma. | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | M | Age | 54-year-old |
| Identity | available | Tissue for Primary Cancer | |
| Case history | Metastasis | ||
| Tissue Metastasized | Genetics | ||
| Life Span | infinite | Crisis PDL | |
| Morphology | epithelial-like | Character | |
| Classify | tumor | Established by | Sirisinha, S. |
| Registered by | Okada, S. | Regulation for Distribution | |
| Comment | Year | 2015 | |
| Medium | Ham's F-12 medium with 10% FBS | Methods for Passages | 0.5% Trypsin - 0.2% EDTA |
| Cell Number on Passage | Split ratio = 1/5 | Race | |
| CO2 Conc. | 5% | Tissue Sampling | intrahepatic bile duct |
| Tissue Type |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Reference | |
|---|---|
| Pubmed id:1666951 | Establishment and characterization of a cholangiocarcinoma cell line from a Thai patient with intrahepatic bile duct cancer. Sirisinha S,Tengchaisri T,Boonpucknavig S,Prempracha N,Ratanarapee S,Pausawasdi A Asian Pac J Allergy Immunol. 1991 Dec;9(2):153-7 |
LOT Information
Viability/Growth rate/Cell number are represented as actual values measured at lot presentation in JCRB, but are not guaranteed values. Additionally, the doubling time is a rough value measured during passages.| Cell No. | JCRB1657 | Cell Name | HuCCA-1 |
|---|---|---|---|
| LOT No. | 02152017 | Lot Specification | distribution |
| Medium | Ham's F-12 medium with 10% heat inactivated fetal bovine serum(SIGMA12J396) | Temperature | 37 C |
| Cell Density at Seeding | 1.6-5.6x10^5 cells/sq.cm | Methods for Passages | Cells were harvested after treatment with 0.5% trypsin and 0.02% EDTA.Split ratio=1/5 |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 2.7x10^6 |
| Viability at cell freezing (%) | 98.00 | Antibiotics Used | free |
| Passage Number | p14* | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:12 D13S317:8 D7S820:10,11 D16S539:11,12 VWA:14,19 TH01:9 AM:X TPOX:9 CSF1PO:10,11 |
| Adhesion | Yes | Exoteric Gene | NT |
| Medium for Freezing | BAMBANKER(LYMPHOTEC Inc.,CS-02-001,NIPPON Genetics Co., LTD) | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | NT | Additional information | Mycoplasma was eliminated with plasmocure. |
| Cell No. | JCRB1657 | Cell Name | HuCCA-1 |
|---|---|---|---|
| LOT No. | 02052021 | Lot Specification | distribution |
| Medium | Ham's F-12 medium with 10% fetal bovine serum (FBS; Sigma Cat. # 172012) | Temperature | 37 C |
| Cell Density at Seeding | 1.1 - 1.4 x 10^5 cells/mL | Methods for Passages | Cells were harvested after treatment with 0.25% trypsin and 0.02% EDTA. |
| Doubling Time | approx. 31 hrs. | Cell Number in Vial (cells/1ml) | 1.2 x 10^6 |
| Viability at cell freezing (%) | 99.4 | Antibiotics Used | free |
| Passage Number | Unknown (15 at bank) | PDL | |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | |
| Chromosome Mode | Chromosome Information | ||
| Surface Antigen | DNA Profile (STR) | ||
| Adhesion | Yes | Exoteric Gene | |
| Medium for Freezing | 10% DMSO, 20% FBS - F12 | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | 95.2 | Additional information |